SU1605914A3 - Способ стабилизации высокоочищенного фактора некроза опухоли из плазмы или сыворотки кролика, индуцированного липополисахаридами - Google Patents
Способ стабилизации высокоочищенного фактора некроза опухоли из плазмы или сыворотки кролика, индуцированного липополисахаридами Download PDFInfo
- Publication number
- SU1605914A3 SU1605914A3 SU833571944A SU3571944A SU1605914A3 SU 1605914 A3 SU1605914 A3 SU 1605914A3 SU 833571944 A SU833571944 A SU 833571944A SU 3571944 A SU3571944 A SU 3571944A SU 1605914 A3 SU1605914 A3 SU 1605914A3
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- factor
- activity
- globulin
- protamine
- tumor
- Prior art date
Links
- 241000283973 Oryctolagus cuniculus Species 0.000 title claims description 7
- 238000000034 method Methods 0.000 title claims description 7
- 239000002158 endotoxin Substances 0.000 title claims description 6
- 210000002966 serum Anatomy 0.000 title claims description 5
- 229920006008 lipopolysaccharide Polymers 0.000 title claims description 4
- 230000000087 stabilizing effect Effects 0.000 title description 4
- 206010054094 Tumour necrosis Diseases 0.000 title 1
- 230000001338 necrotic effect Effects 0.000 claims abstract description 33
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 28
- 230000000694 effects Effects 0.000 claims abstract description 26
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims 2
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 230000006641 stabilisation Effects 0.000 claims 1
- 238000011105 stabilization Methods 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 4
- 239000008280 blood Substances 0.000 abstract description 4
- 102000006395 Globulins Human genes 0.000 abstract 5
- 108010044091 Globulins Proteins 0.000 abstract 5
- 102000007327 Protamines Human genes 0.000 abstract 5
- 108010007568 Protamines Proteins 0.000 abstract 5
- 229940048914 protamine Drugs 0.000 abstract 5
- 238000000746 purification Methods 0.000 abstract 3
- 238000000926 separation method Methods 0.000 abstract 3
- 230000003327 cancerostatic effect Effects 0.000 abstract 2
- 238000004108 freeze drying Methods 0.000 abstract 2
- 230000007774 longterm Effects 0.000 abstract 2
- 241000972773 Aulopiformes Species 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 235000019515 salmon Nutrition 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 23
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
- 239000011780 sodium chloride Substances 0.000 description 11
- 102000003390 tumor necrosis factor Human genes 0.000 description 8
- 206010028851 Necrosis Diseases 0.000 description 6
- 230000017074 necrotic cell death Effects 0.000 description 6
- 239000008055 phosphate buffer solution Substances 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000002008 hemorrhagic effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- 208000020154 Acnes Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241001602876 Nata Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57129560A JPS5920225A (ja) | 1982-07-27 | 1982-07-27 | ガン壊死因子の安定化方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU1605914A3 true SU1605914A3 (ru) | 1990-11-07 |
Family
ID=15012508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU833571944A SU1605914A3 (ru) | 1982-07-27 | 1983-04-05 | Способ стабилизации высокоочищенного фактора некроза опухоли из плазмы или сыворотки кролика, индуцированного липополисахаридами |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPS5920225A (OSRAM) |
| SU (1) | SU1605914A3 (OSRAM) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2629000B2 (ja) * | 1986-07-18 | 1997-07-09 | 中外製薬株式会社 | 安定な顆粒球コロニー刺激因子含有製剤 |
| KR20220114183A (ko) * | 2021-02-08 | 2022-08-17 | 주식회사 대웅 | 장기 저장이 가능한 보툴리눔 독소 동결건조 제형 조성물 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55108821A (en) * | 1979-02-14 | 1980-08-21 | Kanebo Ltd | Preparation of antitumor agent |
-
1982
- 1982-07-27 JP JP57129560A patent/JPS5920225A/ja active Granted
-
1983
- 1983-04-05 SU SU833571944A patent/SU1605914A3/ru active
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0375530B2 (OSRAM) | 1991-12-02 |
| JPS5920225A (ja) | 1984-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR860000842B1 (ko) | 종양 괴사 인자의 안정화 방법 | |
| US4824938A (en) | Water-soluble dry solid containing proteinaceous bioactive substance | |
| JP2512453B2 (ja) | 天然のコロニ−促進因子―１の精製 | |
| NL8900779A (nl) | Eiwit dat de werking van tumor necrose factor tegengaat, dna dat voor zulk eiwit codeert, een vector die zulk dna bevat, een met die vector getransformeerde gastheercel en een farmaceutisch preparaat dat dat eiwit bevat. | |
| US3637640A (en) | Orgotein stabilized with saccharide process and products | |
| EP0090892B1 (en) | Process for the purification of physiologically active substance having antitumour activity | |
| US4124702A (en) | Polynucleotides active as inducers of interferon production in living animal cells | |
| JPS59137417A (ja) | 人尿由来コロニ−形成刺激因子及びカリクレインの製造法 | |
| JPH03505334A (ja) | 凍結乾燥されたペプチド製剤 | |
| US4529594A (en) | Protein having antitumor activity | |
| JPS63165328A (ja) | 組織タンパクｐｐ４含有医薬 | |
| SU1605914A3 (ru) | Способ стабилизации высокоочищенного фактора некроза опухоли из плазмы или сыворотки кролика, индуцированного липополисахаридами | |
| JPH0713026B2 (ja) | 血友病ａ抑制患者の治療のための製剤及び該製剤の製造方法 | |
| JP2566919B2 (ja) | α−インタ−フエロンの製造方法 | |
| JPH0222233A (ja) | スーパーオキシドディスムターゼ組成物 | |
| Russo et al. | Renal clearance of essential amino acids: threonine and phenylalanine | |
| EP0539408A1 (en) | STABILIZED COMPOSITION CONTAINING A FIBROBLAST GROWTH FACTOR. | |
| KR970009890B1 (ko) | 혈소판감소증치료제 | |
| Kim et al. | Immobilization of urokinase on agarose matrices | |
| JPS5959625A (ja) | ガン壊死因子を安定化する方法 | |
| JPH04198195A (ja) | Ｃｐｂ―ｉの安定化方法及び製剤組成物 | |
| JPH0375529B2 (OSRAM) | ||
| JPH04187640A (ja) | 経口・経皮免疫機能促進剤、動物用経口・経皮免疫機能促進剤 | |
| EP0134247A1 (en) | Protein with oncostatic effect, process for its preparation, and oncostatic drug containing it | |
| US5023320A (en) | Process for the purification of physiologically active substance having antitumor activity |